EDAP
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Edap Tms S.a.
- Nom
- Edap Tms S.a.
- Secteur
- Healthcare
- Industrie
- Medical - Specialties
- Bourse
- NASDAQ
- Capitalisation
- $178.2M
- Employés
- 289
- PDG
- Ryan Rhodes
- Site web
- https://focalone.com
- Marché
- ACRVFBIOHYPRINCRLUNGMDAI
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 20 000 titres (~95 000,00 $ US)
- Insiders
- Horn David R.LEVINE JOSHUA
- Total bought
-
$95,000
Avg buy (VWAP, 90d window) $4.75 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-14 | Annen Steven | Buy · P | 5,000 | $4.75 | $23,750 | Form 4 |
| 2026-08-14 | Horn David R. | Buy · P | 10,000 | $4.75 | $47,500 | Form 4 |
| 2026-08-14 | LEVINE JOSHUA | Buy · P | 10,000 | $4.75 | $47,500 | Form 4 |
| 2026-08-14 | Mobeck Kenneth S. | Buy · P | 5,000 | $4.75 | $23,750 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a meaningful insider cluster buy signal (score 75, confidence 0.7) following the Q2 2026 earnings call and the FocalTherics/HIFU strategic pivot, the severely distressed financial foundation — persistent net…
The first sentence of the analysis written for EDAP on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.54 · operating margin -36% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 42.5% | 41.4% | 40.4% | 43.9% | 41.8% | |
| Ebit Margin | -40.2% | -28.8% | -33.6% | -3.5% | -3.7% | |
| Ebitda Margin | -35.4% | -24.8% | -30.4% | -0.6% | 0.7% | |
| Operating Profit Margin | -35.6% | -32.0% | -32.8% | -7.7% | -3.7% | |
| Pretax Profit Margin | -41.4% | -29.2% | -34.0% | -3.8% | 2.0% | |
| Continuous Operations Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Net Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Bottom Line Profit Margin | -41.5% | -29.7% | -35.0% | -5.3% | 1.6% | |
| Current Ratio | 1.539 | 1.848 | 2.844 | 4.170 | 3.754 | |
| Quick Ratio | 1.245 | 1.359 | 2.296 | 3.627 | 3.336 | |
| Solvency Ratio | -0.435 | -0.364 | -0.556 | -0.045 | 0.096 | |
| Cash Ratio | 0.469 | 0.789 | 1.575 | 2.908 | 2.628 | |
| Price To Earnings Ratio | -4.218 | -4.185 | -8.380 | -116.710 | 241.633 | |
| Price To Earnings Growth Ratio | -0.080 | 0.398 | -0.015 | 0.238 | -1.760 | |
| Forward Price To Earnings Growth Ratio | -0.080 | 0.398 | -0.015 | 0.238 | -1.760 | |
| Price To Earnings Diluted Ratio | -4.218 | -4.185 | -8.380 | -116.710 | 235.161 | |
| Price To Earnings Diluted Growth Ratio | -0.080 | 0.398 | -0.015 | 0.243 | -1.700 | |
| Price To Book Ratio | 6.345 | 1.946 | 3.105 | 4.780 | 3.381 | |
| Price To Sales Ratio | 1.741 | 1.241 | 2.925 | 6.213 | 3.841 | |
| Price To Free Cash Flow Ratio | -5.557 | -4.500 | -9.314 | -65.756 | 60.466 | |
| Price To Operating Cash Flow Ratio | -7.507 | -5.858 | -12.040 | -113.225 | 38.075 | |
| Debt To Assets Ratio | 0.350 | 0.162 | 0.092 | 0.093 | 0.130 | |
| Debt To Equity Ratio | 1.426 | 0.340 | 0.148 | 0.131 | 0.200 | |
| Debt To Capital Ratio | 0.588 | 0.254 | 0.129 | 0.116 | 0.167 | |
| Long Term Debt To Capital Ratio | 0.450 | 0.050 | 0.034 | 0.048 | 0.090 | |
| Financial Leverage Ratio | 4.069 | 2.104 | 1.608 | 1.412 | 1.543 | |
| Working Capital Turnover Ratio | 2.716 | 1.546 | 1.010 | 0.932 | 1.202 | |
| Operating Cash Flow Ratio | -0.442 | -0.359 | -0.532 | -0.139 | 0.248 | |
| Operating Cash Flow Sales Ratio | -0.232 | -0.212 | -0.243 | -0.055 | 0.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.351 | 1.302 | 1.293 | 1.722 | 0.630 | |
| Debt Service Coverage Ratio | -2.823 | -1.825 | -4.477 | -0.320 | 0.041 | |
| Interest Coverage Ratio | -31.852 | -87.008 | -85.401 | -25.339 | -31.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -2.024 | -1.570 | -3.652 | -0.877 | 1.620 | |
| Operating Cash Flow Coverage Ratio | -0.593 | -0.976 | -1.742 | -0.322 | 0.444 | |
| Capital Expenditure Coverage Ratio | -2.849 | -3.312 | -3.417 | -1.385 | 2.700 | |
| Dividend Paid And Capex Coverage Ratio | -2.849 | -3.312 | -3.417 | -1.385 | 2.700 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.328 | -3.997 | -7.705 | -903.397 | 427.395 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 42.5% | ▲1.1% | ▲0.5% |
| Ebit Margin | -40.2% | ▼-11.4% | ▼-18.3% |
| Ebitda Margin | -35.4% | ▼-10.6% | ▼-17.3% |
| Operating Profit Margin | -35.6% | ▼-3.6% | ▼-13.3% |
| Pretax Profit Margin | -41.4% | ▼-12.2% | ▼-20.1% |
| Continuous Operations Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Net Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Bottom Line Profit Margin | -41.5% | ▼-11.8% | ▼-19.5% |
| Current Ratio | 1.539 | ▼-0.309 | ▼-1.292 |
| Quick Ratio | 1.245 | ▼-0.114 | ▼-1.127 |
| Solvency Ratio | -0.435 | ▼-0.071 | ▼-0.174 |
| Cash Ratio | 0.469 | ▼-0.320 | ▼-1.205 |
| Price To Earnings Ratio | -4.218 | ▼-0.033 | ▼-25.846 |
| Price To Earnings Growth Ratio | -0.080 | ▼-0.477 | ▲0.164 |
| Forward Price To Earnings Growth Ratio | -0.080 | ▼-0.477 | ▲0.164 |
| Price To Earnings Diluted Ratio | -4.218 | ▼-0.033 | ▼-24.552 |
| Price To Earnings Diluted Growth Ratio | -0.080 | ▼-0.477 | ▲0.151 |
| Price To Book Ratio | 6.346 | ▲4.400 | ▲2.434 |
| Price To Sales Ratio | 1.741 | ▲0.500 | ▼-1.451 |
| Price To Free Cash Flow Ratio | -5.557 | ▼-1.057 | ▼-0.625 |
| Price To Operating Cash Flow Ratio | -7.507 | ▼-1.649 | ▲12.604 |
| Debt To Assets Ratio | 0.350 | ▲0.189 | ▲0.185 |
| Debt To Equity Ratio | 1.426 | ▲1.086 | ▲0.977 |
| Debt To Capital Ratio | 0.588 | ▲0.334 | ▲0.337 |
| Long Term Debt To Capital Ratio | 0.450 | ▲0.400 | ▲0.316 |
| Financial Leverage Ratio | 4.069 | ▲1.965 | ▲1.922 |
| Working Capital Turnover Ratio | 2.716 | ▲1.171 | ▲1.235 |
| Operating Cash Flow Ratio | -0.442 | ▼-0.083 | ▼-0.197 |
| Operating Cash Flow Sales Ratio | -0.232 | ▼-0.020 | ▼-0.104 |
| Free Cash Flow Operating Cash Flow Ratio | 1.351 | ▲0.049 | ▲0.091 |
| Debt Service Coverage Ratio | -2.823 | ▼-0.999 | ▼-0.943 |
| Interest Coverage Ratio | -31.852 | ▲55.157 | ▲20.268 |
| Short Term Operating Cash Flow Coverage Ratio | -2.024 | ▼-0.454 | ▼-0.724 |
| Operating Cash Flow Coverage Ratio | -0.593 | ▲0.383 | ▲0.045 |
| Capital Expenditure Coverage Ratio | -2.849 | ▲0.463 | ▼-1.197 |
| Dividend Paid And Capex Coverage Ratio | -2.849 | ▲0.463 | ▼-1.197 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.328 | ▼-1.332 | ▲93.278 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $123.2M | $79.6M | $176.7M | $342.4M | $169.2M | |
| Enterprise value | $133.5M | $63.7M | $141.7M | $288.6M | $132.1M | |
| EV / Sales | 1.89x | 0.99x | 2.35x | 5.24x | 3.00x | |
| EV / Op. cash flow | -8.13x | -4.69x | -9.65x | -95.45x | 29.71x | |
| EV / Free cash flow | -6.02x | -3.60x | -7.47x | -55.43x | 47.18x | |
| EV / EBITDA | -5.33x | -4.00x | -7.71x | -903.40x | 427.39x | |
| Net debt / EBITDA | -0.41x | 1.00x | 1.91x | 168.24x | -120.32x | |
| Current ratio | 1.54x | 1.85x | 2.84x | 4.17x | 3.75x | |
| Income quality | 0.56x | 0.71x | 0.69x | 1.03x | 6.35x | |
| Graham number | — | — | — | — | $1 | |
| Graham net-net | -$1 | $0 | $1 | $1 | $1 | |
| Tax burden | 100.2% | 101.5% | 103.1% | 139.9% | 78.4% | |
| Interest burden | 102.8% | 101.3% | 101.1% | 108.7% | -55.4% | |
| Working capital | $20.0M | $32.1M | $50.9M | $68.8M | $49.4M | |
| Invested capital | $36.1M | $45.9M | $62.6M | $77.9M | $57.7M | |
| Return on assets | -37.1% | -22.1% | -23.1% | -2.9% | 0.9% | |
| Operating ROA | -30.5% | -23.1% | -20.6% | -4.8% | -2.4% | |
| Return on tangible assets | -39.4% | -23.0% | -24.1% | -3.0% | 0.9% | |
| Return on equity | -151.1% | -46.5% | -37.2% | -4.1% | 1.4% | |
| Return on invested capital | -49.2% | -35.4% | -28.7% | -5.1% | -2.0% | |
| Return on capital employed | -60.2% | -42.6% | -31.0% | -5.4% | -2.7% | |
| Earnings yield | -23.8% | -23.9% | -12.0% | -0.9% | 0.4% | |
| Free cash flow yield | -18.0% | -22.2% | -10.7% | -1.5% | 1.7% | |
| Capex / Op. cash flow | -35.1% | -30.2% | -29.3% | -72.2% | 37.0% | |
| Capex / Depreciation | 169.0% | 159.9% | 224.6% | 136.0% | 85.7% | |
| Capex / Sales | 8.1% | 6.4% | 7.1% | 4.0% | 3.7% | |
| SG&A / Sales | 63.7% | 61.4% | 61.7% | 42.7% | 37.7% | |
| R&D / Sales | 12.1% | 12.1% | 11.5% | 8.9% | 10.8% | |
| Stock comp / Sales | 3.6% | 5.1% | 11.4% | 3.8% | 4.3% | |
| Intangibles / Total assets | 5.9% | 4.1% | 3.8% | 3.1% | 4.1% | |
| Days sales outstanding | 117d | 116d | 102d | 99d | 100d | |
| Days payables outstanding | 158d | 122d | 114d | 78d | 78d | |
| Operating cycle | 215d | 295d | 256d | 238d | 207d | |
| Cash conversion cycle | 56d | 173d | 142d | 160d | 129d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
- 2026-08-04 McDonald''s Corp (MCD) (Q2 2026) Earnings Call Highlights: Navigating US Execution Challenges While Driving Global Growth System-wide Sales Growth: 4% increase in constant currency for the second quarter; 5% increase for the first half of the year.Global Comparable Sales: 1.3% grow
- 2026-06-01 Edap Tms Unveils FocalTherics Pivot, Targets 40% Growth on HIFU Expansion Edap Tms NASDAQ: EDAP used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company''s Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.
- 2026-05-29 EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
- 2026-05-29 EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.
- 2026-05-21 EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference , May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference